Almirall has a history of more than 40 years as a research-driven company with the goal to provide society with innovative medicines that help to improve people's health and quality of life.
Our scientists' dedication to excellence and innovation is essential in the discovery and development of safe and effective medicines to treat serious diseases within our therapeutic focus of respiratory and autoimmune indications. This is supplemented by an international network of collaborations with leading private and public research institutions in our field.
Almirall's acquisition of Hermal in 2007 -a leading dermatology company in Europe- has further strengthened our development pipeline and expertise in the area of dermatological diseases.
Medicines discovered and developed by Almirall scientists
- Almirall invests over 23% of net sales in research and development
- Over 20% of Almirall professionals work in R&D
- A clear therapeutic focus approach has led to a strong pipeline
- Almirall has R&D centres at 3 sites in Europe
Strong product pipeline
Almirall carries out its clinical trials according to local regulations in the countries where the trials are performed and following international declarations and guidelines, Declaration of Helsinki and Good Clinical Practices.
The Declaration of Helsinki objective is to guarantee the rights of the clinical trial participants.
Good Clinical Practice (GCPs) is an international ethical and scientific quality standard to ensure the safety and well being of the clinical trial participants and the quality of the results.
The GCP guideline was issued by the International Conference on Harmonisation (ICH), with Health Authority representatives from Europe, the US and Japan and the pharmaceutical industry.
Almirall performs global and complex clinical trials efficiently in terms of time and quality, relying on our scientific and ethical standards and a profound knowledge in the clinical development of new pharmaceutical products.